Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
WO 17.08.2006
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2006/004599 Applicant NEW YORK BLOOD CENTER Inventor JIANG, Shibo
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
2.20210353620METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS
US 18.11.2021
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No 17320069 Applicant The University of Vermont and State Agricultural College Inventor Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

3.3101131COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS­COV-2 VACCINES
CA 31.07.2021
Int.Class C12N 15/15
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
15Protease inhibitors, e.g. antithrombin, antitrypsin, hirudin
Appl.No 3101131 Applicant JANSSEN PHARMACEUTICALS, INC. Inventor

P217625CA00 CR U6043CAN P1
- 269 -
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS
INFECTION - SARS-COV-2 VACCINES
Abstract
The invention relates to immunogenic compositions and vaccines containing a
coronavirus
(e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein
or a
polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV;
SARS-CoV-
2)) protein and uses thereof. The invention also provides methods of treating
and/or
preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2))
infection
by administering an immunogenic composition or vaccine to a subject (e.g., a
human). The
invention also provides methods of detecting and/or monitoring a protective
anti-
coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody
response (e.g.,
anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response,
e.g., anti-
Spike antibody response, e.g., anti-Spike neutralizing antibody response). The
present
invention relates to isolated nucleic and/or recombinant nucleic acid encoding
a
coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the
coronavirus S
proteins, as well as to the use of the nucleic acids and/or proteins thereof
in vaccines.
<1093966>
Date Recue/Date Received 2020-11-28

4.WO/2021/186190CORONAVIRUS ANTIBODY
WO 23.09.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/GB2021/050685 Applicant IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor XU, Xiao-Ning
An antibody or antigen-binding fragment thereof is described which binds to the spike protein S2 domain of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and/ or severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The antibodies can be used in the diagnosis and treatment of coronavirus infection. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The invention also extends to methods of making and using the antibodies, for example in the diagnosis and therapy of coronavirus infections.
5.WO/2005/018535COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
WO 03.03.2005
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2004/015864 Applicant WYETH HOLDINGS CORPORATION Inventor SIBER, George, R.
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
6.20210330663PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, PREVENTING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
US 28.10.2021
Int.Class A61K 31/4706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
Appl.No 17371009 Applicant CENTRE FOR DIGESTIVE DISEASES Inventor Thomas Julius BORODY

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™), wherein optionally each or both of the opaganib and the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™) are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, liquid or powder.

7.WO/2021/257607TREATMENT FOR HUMAN CORONAVIRUS INFECTION
WO 23.12.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/037486 Applicant THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND Inventor BIX, Gregory Jaye
Treating a human coronavirus (hCoV) infection includes administering an effective amount of an inhibitor of an α5- or αv-containing integrin to a subject in need thereof. The integrin inhibitor can be ATN-161. The hCoV can be SARS-CoV or SARS-CoV-2.
8.20070026014Interferon beta in severe acute respiratory syndrome (sars)
US 01.02.2007
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 10553135 Applicant ARES TRADING S.A. Inventor de Luca Giampiero

The us of an interferon (IFN) for the manufacture of a medicament useful for treatment and/or prevention of Severe Acute Respiratory Syndrome (SARS) is described in the present invention.

9.WO/2021/229561ANTI-SARS-COV-2 ANTIBODIES
WO 18.11.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IL2021/050335 Applicant THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR) Inventor NOY-PORAT, Tal
The present invention is directed to isolated monoclonal antibodies which binds to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, and to uses thereof for treating COVID-19.
10.WO/2022/010912ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/040533 Applicant FLAGSHIP PIONEERING INNOVATIONS VI, LLC Inventor GRIGORYAN, Gevorg
The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g.,COVID-19).